Trial reportNature medicine2023
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.
Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled TrialMulticenter Study
In one paragraph
Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
20.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 71 citations in OpenAlex.
- Continuous infusion of granulocyte colony-stimulating factor is associated with an advantage in neutrophil recovery in pediatric oncologic disorders.Cancer chemotherapy and pharmacology · 2026Trial
- Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplant.Annals of hematology · 2026Trial
- Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.Blood cancer journal · 2024Trial
- Calcium and Other Electrolyte Management in Patients Undergoing Leukocytapheresis Collections: Review and Recommendations From the American Society for Apheresis Clinical Applications Committee.Journal of clinical apheresis · 2026Review
- From bud to stem: dynamics of hematopoietic stem cells that drive homing and mobilization.Current opinion in hematology · 2026Review
- Decoding GPCR signaling reprogramming in cancer: molecular mechanisms and therapeutic implications.Molecular medicine (Cambridge, Mass.) · 2026Review
- Single-cell technologies drive mechanistic insights and therapeutic translation in skeletal system research.iScience · 2026Review
- Emerging Considerations in Transfusion Medicine: Hematopoietic Stem and Progenitor Cell Collection for Gene Therapy for Sickle Cell Disease and Transfusion-Dependent Thalassemia.Clinics in laboratory medicine · 2026Review
- Lifespan-Regulated CAR-Macrophages from Myeloid Progenitors for Enhanced Colorectal Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mapping Hematopoietic Fate after Transplantation.Stem cell reviews and reports · 2025Review
- Cyp7b1-inhibiting azoles as novel enhancers of hematopoietic stem and progenitor cell mobilization.bioRxiv : the preprint server for biology · 2025Article
- Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Moving Beyond G-CSF Mobilization-Learning From a 15-Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma.Cancer medicine · 2025Article
- Targeting the chemokine receptor CXCR4 for cancer therapies.Biomarker research · 2025Review
- SERCA-mediated endoplasmic reticulum stress facilitates hematopoietic stem cell mobilization.Stem cell research & therapy · 2025Article
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- Article
- Development of VLA4 and CXCR4 Antagonists for the Mobilization of Hematopoietic Stem and Progenitor Cells.Biomolecules · 2024Review
- Review
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 18 institutions in 6 countries.
Zachary D CreesDivision of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA. zcrees@wustl.edu.ORCID http://orcid.org/0000-0003-3215-8454
Michael P RettigDivision of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-1091-0564
Reyka G JayasingheDivision of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-2368-4890
Keith Stockerl-GoldsteinDivision of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-7234-1715
Sarah M LarsonDivision of Hematology-Oncology, UCLA School of Medicine, Los Angeles, CA, USA.
Illes ArpadDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Giulio A MiloneUnità di Trapianto Emopoietico, Azienda Ospedaliero Universitaria 'Policlinico-San Marco', Catania, Italy.
Massimo MartinoUnit of Stem Cell Transplantation and Cellular Therapies, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.ORCID http://orcid.org/0000-0002-3987-419X
Patrick StiffLoyola University Medical Center, Maywood, CA, USA.ORCID http://orcid.org/0000-0001-8265-9340
Douglas SborovHuntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.
Denise PereiraSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.ORCID http://orcid.org/0000-0002-1992-7899
Ivana MicallefDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Gemma Moreno-JiménezDepartment of Hematology, Ramon y Cajal University Hospital, Madrid, Spain.ORCID http://orcid.org/0000-0003-0712-8077
Gabor MikalaCenter Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.ORCID http://orcid.org/0000-0003-2204-7398
Maria Liz Paciello CoronelHospital University 12 De Octubre, Madrid, Spain.
Udo HoltickDepartment I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.
John HiemenzDivision of Hematology-Oncology, University of Florida, Gainesville, FL, USA.
Muzaffar H QazilbashDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nancy HardyMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Tahir LatifDivision of Hematology-Oncology, University of Cincinnati, Cincinnati, OH, USA.
Irene García-CadenasDepartment of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Abi Vainstein-HarasBioLineRx, Ltd., Modi'in, Israel.
Ella SoraniBioLineRx, Ltd., Modi'in, Israel.
Irit Gliko-KabirBioLineRx, Ltd., Modi'in, Israel.
Inbal GoldsteinBioLineRx, Ltd., Modi'in, Israel.
Debby IckowiczBioLineRx, Ltd., Modi'in, Israel.
Liron Shemesh-DarvishBioLineRx, Ltd., Modi'in, Israel.
Shaul KadoshStatExcellence, Ltd., Kyriat Mozkin, Israel.
Feng GaoDivision of Public Health Sciences, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Mark A SchroederDivision of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-4924-8990
Ravi VijDivision of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
John F DiPersioDivision of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-0429-3133
Washington University in St. Louis · USProtalix BioTherapeutics (Israel) · ILAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITHospital de Sant Pau · ESInstituto Cajal · ESLoyola University Medical Center · USMayo Clinic in Arizona · USPoliclinico Universitario di Catania · ITResearch Institute Hospital 12 de Octubre · ESThe University of Texas MD Anderson Cancer Center · USUniversity of California, Los Angeles · USUniversity of Cincinnati · USUniversity of Cologne · DEUniversity of Debrecen · HUUniversity of Florida · USUniversity of Maryland, Baltimore · USUniversity of Miami Health System · USUniversity of Utah · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MTargeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6MOptimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological MalignanciesR35CA210084 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio · 2017 to 2026
$7.8MBM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIESR50CA211466 · NCI · WASHINGTON UNIVERSITY · PI Michael Rettig · 2016 to 2026
$2.3MNCI NIH HHS P30 CA091842NCI NIH HHS P50 CA171963NCI NIH HHS R35 CA210084NCI NIH HHS R50 CA211466
Abstract
Autologous hematopoietic stem cell transplantation (ASCT) improves survival in multiple myeloma (MM). However, many individuals are unable to collect optimal CD34
Indexed as
Hematopoietic Stem Cell TransplantationHeterocyclic CompoundsMultiple MyelomaAdultAntigens, CD34Granulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem CellsHumansImmunologic FactorsProspective StudiesTransplantation, AutologousAntigens, CD34Granulocyte Colony-Stimulating FactorHeterocyclic CompoundsImmunologic Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.